{"id":"escalated-beacopp","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD137 is expressed on activated T cells and plays a role in the regulation of immune responses. By targeting CD137, Beacopan aims to enhance anti-tumor immune responses.","oneSentence":"Beacopan is a monoclonal antibody that targets CD137, a member of the tumor necrosis factor receptor superfamily.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:45.684Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT03159897","phase":"PHASE3","title":"FIL Study on ABVD DD-DI as Upfront Therapy in HL.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2017-08-01","conditions":"Hodgkin Lymphoma","enrollment":500},{"nctId":"NCT00049595","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-08","conditions":"Lymphoma","enrollment":552},{"nctId":"NCT02661503","phase":"PHASE3","title":"HD21 for Advanced Stages","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2016-07","conditions":"Classical Hodgkin Lymphoma","enrollment":1500},{"nctId":"NCT00678327","phase":"PHASE3","title":"Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2008-08-29","conditions":"Lymphoma","enrollment":1202},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT00822120","phase":"PHASE2","title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-07","conditions":"Lymphoma, Nonneoplastic Condition","enrollment":371},{"nctId":"NCT01118026","phase":"PHASE2","title":"Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-09","conditions":"Lymphoma","enrollment":101},{"nctId":"NCT02298283","phase":"PHASE2","title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-04","conditions":"Hodgkin Lymphoma","enrollment":40},{"nctId":"NCT00433433","phase":"PHASE3","title":"Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-10","conditions":"Lymphoma","enrollment":1952},{"nctId":"NCT00515554","phase":"PHASE3","title":"HD18 for Advanced Stages in Hodgkins Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2008-05","conditions":"Hodgkins Lymphoma","enrollment":1500},{"nctId":"NCT00795613","phase":"PHASE2","title":"Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)","status":"UNKNOWN","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2008-06","conditions":"HODGKIN LYMPHOMA","enrollment":450},{"nctId":"NCT01251107","phase":"PHASE3","title":"Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2000-03","conditions":"Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT01304849","phase":"NA","title":"Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes","status":"COMPLETED","sponsor":"Cancer Institute WIA","startDate":"2011-01","conditions":"Hodgkin's Lymphoma","enrollment":50},{"nctId":"NCT00392314","phase":"PHASE2","title":"Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2006-10","conditions":"Hodgkin Lymphoma","enrollment":365},{"nctId":"NCT00305149","phase":"NA","title":"Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"1999-07","conditions":"Classical Hodgkin Lymphoma, Nodular Sclerosis, Mixed Cellularity","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":106,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BLEOMICINE TEVA","VEPESID","DOXORUBICINE TEVA","ENDOXAN","VINCRISTINE TEVA"],"phase":"phase_2","status":"active","brandName":"ESCALATED BEACOPP","genericName":"ESCALATED BEACOPP","companyName":"Ospedale Santa Croce-Carle Cuneo","companyId":"ospedale-santa-croce-carle-cuneo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Beacopan is a monoclonal antibody that targets CD137, a member of the tumor necrosis factor receptor superfamily. Used for Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}